P2B-001の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

Pharma Two Bが開発中のP2B-001は、低用量ドパミン作動薬である徐放性プラミペキソールと低用量モノアミン酸化酵素B（MAO-B）阻害薬であるラサギリンの新しい1日1回投与の併用療法であり、パーキンソン病治療薬として特別に開発されました。

この2つの薬剤は、互いに助け合う2つの異なるメカニズムで作用するため、併用することでそれぞれの薬剤よりも優れた効果が得られると考えられる理由があります。治療効果を失うことなく、より低用量で使用することができます。したがって、P2B001の開発は、改良された製剤でこれら2つの薬剤の低用量の組み合わせを提供することを意図しており、それぞれの薬剤を単独で服用したり、現在市販されている薬剤を併用したりするよりも、パーキンソン病の症状を抑制する効果が高く、副作用が少ないと期待されています。

Pharma Two Bは、P2B001の早期パーキンソン病に対する1日1回、無滴定の治療薬としての有効性と安全性を調査するフェーズIIb試験とフェーズIII試験を完了しました。FDAへのNDA申請が準備中です。すでに終了した臨床試験では、P2B001を投与された患者において、プラセボを投与された患者と比較してパーキンソン病症状の有意な改善が認められました。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）におけるパーキンソン病向けP2B-001について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるP2B-001の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 P2B-001市場の評価

• パーキンソン病におけるP2B-001の市場見通し
• 主要7市場の分析
  • 主要7市場のパーキンソン病向けP2B-001の市場規模
• 市場の分析：国別
  • 米国のパーキンソン病向けP2B-001の市場規模
  • ドイツのパーキンソン病向けP2B-001の市場規模
  • 英国のパーキンソン病向けP2B-001の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: P2B-001, Clinical Trial Description, 2023
• Table 2: P2B-001, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: P2B-001 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: P2B-001 Market Size in the US, in USD million (2019-2032)
• Table 7: P2B-001 Market Size in Germany, in USD million (2019-2032)
• Table 8: P2B-001 Market Size in France, in USD million (2019-2032)
• Table 9: P2B-001 Market Size in Italy, in USD million (2019-2032)
• Table 10: P2B-001 Market Size in Spain, in USD million (2019-2032)
• Table 11: P2B-001 Market Size in the UK, in USD million (2019-2032)
• Table 12: P2B-001 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: P2B-001 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: P2B-001 Market Size in the United States, USD million (2019-2032)
• Figure 3: P2B-001 Market Size in Germany, USD million (2019-2032)
• Figure 4: P2B-001 Market Size in France, USD million (2019-2032)
• Figure 5: P2B-001 Market Size in Italy, USD million (2019-2032)
• Figure 6: P2B-001 Market Size in Spain, USD million (2019-2032)
• Figure 7: P2B-001 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: P2B-001 Market Size in Japan, USD million (2019-2032)

"P2B-001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about P2B-001 for Parkinson's disease in the seven major markets. A detailed picture of the P2B-001 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the P2B-001 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the P2B-001 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

P2B-001 being developed by Pharma Two B, is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose Monoamine Oxidase-B (MAO-B) inhibitor, developed specifically for the treatment of Parkinson's disease.

The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each drug. Lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs in an improved formulation that is hoped to be more effective in controlling Parkinson's disease symptoms and with fewer side effects than each of the drugs taken alone or the currently available commercial drugs taken together.

Pharma Two B has completed Phase IIb and Phase III studies investigating P2B001's efficacy and safety as a once-daily, no-titration treatment for early-stage Parkinson's disease. An NDA submission to the FDA is being prepared. In a previously completed clinical trial, a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with a placebo.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the P2B-001 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on P2B-001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the P2B-001 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around P2B-001.
• The report contains forecasted sales of P2B-001 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for P2B-001 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

P2B-001 Analytical Perspective by DelveInsight

• In-depth P2B-001 Market Assessment

This report provides a detailed market assessment of P2B-001 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• P2B-001 Clinical Assessment

The report provides the clinical trials information of P2B-001 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence P2B-001 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to P2B-001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of P2B-001 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of P2B-001 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the P2B-001 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of P2B-001?
• What is the clinical trial status of the study related to P2B-001 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the P2B-001 development?
• What are the key designations that have been granted to P2B-001 for Parkinson's disease?
• What is the forecasted market scenario of P2B-001 for Parkinson's disease?
• What are the forecasted sales of P2B-001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to P2B-001 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. P2B-001 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. P2B-001 Market Assessment

• 5.1. Market Outlook of P2B-001 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of P2B-001 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of P2B-001 in the United States for Parkinson's disease
  • 5.3.2. Market Size of P2B-001 in Germany for Parkinson's disease
  • 5.3.3. Market Size of P2B-001 in France for Parkinson's disease
  • 5.3.4. Market Size of P2B-001 in Italy for Parkinson's disease
  • 5.3.5. Market Size of P2B-001 in Spain for Parkinson's disease
  • 5.3.6. Market Size of P2B-001 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of P2B-001 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options